SCHEMBL7129337

SCHEMBL7129337

CC(=O)Nc1ccccc1Oc1ccc(-c2nnn[nH]2)c(C#N)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
PYGM P11217 4/20 0.39
PYGL P06737 2/20 0.39
PLA2G7 Q13093 5/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CASP1 P29466 1/20 0.38
MAP2K1 Q02750 1/20 0.35
KMT2A Q03164 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116112 0.93 PLA2G7 (0.40) TP53HPGDNPSR1HSD17B10HTT
SCHEMBL7199417 0.89 LMNA (0.40) HSD17B10ALDH1A1MAPTPYGMPYGL
SCHEMBL7198057 0.86 TP53 (0.37) TP53HPGDNPSR1HSD17B10HTT
SCHEMBL7118162 0.81 MAPT (0.58) NPSR1HTTALDH1A1KDM4EMAPT
SCHEMBL7195234 0.81 LMNA (0.42) HSD17B10ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL7123049 0.80 PLA2G7 (0.51) TP53HPGDNPSR1HSD17B10HTT
SCHEMBL7118171 0.79 GAA (0.43) ALDH1A1
SCHEMBL7192138 0.75 MAPT (0.58) NPSR1HTTALDH1A1KDM4EMAPT
SCHEMBL12892206 0.74 ALDH1A1 (0.57) HPGDHSD17B10ALDH1A1KDM4ETSHR
SCHEMBL7126066 0.71 TLR4 (0.43) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM TP53 3165/4885HPGD 919/4885NPSR1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.